These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9126220)

  • 1. Defining the ideal tumor marker for prostate cancer.
    Montie JE; Meyers SE
    Urol Clin North Am; 1997 May; 24(2):247-52. PubMed ID: 9126220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for prostate cancer.
    Wilson SS; Crawford ED
    Clin Prostate Cancer; 2004 Jun; 3(1):21-5. PubMed ID: 15279686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New biomarkers for diagnosis and prognosis of localized prostate cancer.
    Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What can the clinician expect today from PSA determination?].
    Teillac P
    Nucl Med Biol; 1994 Apr; 21(3):455-69. PubMed ID: 9296766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Isoforms of free prostate-specific antigen].
    Haese A; Noldus J; Steuber T; Huland H; Lilja H
    Urologe A; 2004 Jun; 43(6):675-9. PubMed ID: 15221148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent free prostate-specific antigen for first-time prostate biopsy.
    Lee CT; Scardino PT
    Urology; 2001 Apr; 57(4):594-8. PubMed ID: 11306355
    [No Abstract]   [Full Text] [Related]  

  • 7. Beyond PSA testing for prostate cancer.
    Brooks D; Olver IN; Esterman AJ
    Med J Aust; 2018 Jun; 208(10):426-427. PubMed ID: 29848243
    [No Abstract]   [Full Text] [Related]  

  • 8. Report on Prostate Cancer Tumor Marker Workshop 1999.
    Partin AW; Murphy GP; Brawer MK
    Cancer; 2000 Feb; 88(4):955-63. PubMed ID: 10679666
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer and the PCP: the screening dilemma.
    Rosenberg MT; Spring AC; David Crawford E
    Int J Clin Pract; 2015 Dec; 69(12):1438-47. PubMed ID: 26459772
    [No Abstract]   [Full Text] [Related]  

  • 10. Tissue markers in the diagnosis and prognosis of prostatic carcinoma.
    de Matteis A
    Eur Urol; 1992; 21 Suppl 1():66-70. PubMed ID: 1385134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
    Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
    Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond PSA: a need for additional markers for prostate cancer.
    Sartor O
    Clin Prostate Cancer; 2004 Dec; 3(3):135. PubMed ID: 15636677
    [No Abstract]   [Full Text] [Related]  

  • 13. The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials.
    Crawford ED
    Eur Urol; 1999; 35(5-6):511-4. PubMed ID: 10325516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging.
    Lee CT; Oesterling JE
    Semin Surg Oncol; 1995; 11(1):23-35. PubMed ID: 7538692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of tumour marker dual reporting during method transition: PSA high-dose hook effect detected.
    Kittanakom S; Donohue V; Beattie J; Clark L; Kavsak PA
    Clin Biochem; 2018 Nov; 61():45-46. PubMed ID: 30179593
    [No Abstract]   [Full Text] [Related]  

  • 16. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for early prostate cancer detection.
    Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
    Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].
    Martínez Jabaloyas JM; García Morata F; Villamón Fort R; Pastor Hernández F; Gil Salom M; García Sisamón F
    Actas Urol Esp; 2003 Jun; 27(6):442-9. PubMed ID: 12918151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
    Schröder FH; Kranse R; Barbet N; Hop WC; Kandra A; Lassus M
    Prostate; 2000 Feb; 42(2):107-15. PubMed ID: 10617867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.